Skip to content
RKWD
ROCKWOOD RESEARCH · A CORPORATE FILINGS WEBSITE|STRAIGHT FROM THE SOURCE · SEC EDGAR|SPONSOREDYour message on this tape — bid on the Rockwood Ad Exchange · Rockwood Ad Exchange|
Rockwood Research
…

WST

WEST PHARMACEUTICAL SERVICES INC

Surgical & Medical Instruments & Apparatus · SIC 3841CIK 105770Held by 10 tracked managersEDGAR filings ↗10-K/10-Q ↗

SHARE:XLINKEDINEMAIL
Revenue FY2025
$3.07B
Net Income FY2025
$0.49B
EPS (Basic, as reported)
$6.83
Net Margin FY2025
16.1%
ROE FY2025
15.5%
Total Equity
$3.18B
Shares Out
70M
Business description

WEST PHARMACEUTICAL SERVICES INC — Surgical & Medical Instruments & Apparatus. Figures are as reported in each year's original 10-K via SEC EDGAR XBRL company facts (FY2008–FY2025; structured XBRL data begins around 2008). Market-price metrics are not part of EDGAR data.

Annual (fiscal years, as reported)USD millions
i
default rows · click any row to chart itRevenue: 1,509 → 3,074 +8.2% CAGR
Fiscal yearFY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue1,5091,5991,7171,8402,1472,8322,8872,9502,8933,074
Cost of revenue(1,008)(1,086)(1,172)(1,234)(1,379)(1,656)(1,751)(1,821)(1,895)(1,970)
Gross profit5015135456067681,1761,1361,1299991,104
Research & development(37)(39)(40)(39)(47)(53)(58)(68)(69)(74)
Selling, general & administrative(240)(243)(263)(273)(302)(363)(317)(353)(338)(394)
Operating income197229240297407752734676570585
Interest expense(8)(8)(8)(8)(8)(8)(8)(9)(3)0
Other income (expense), net230(5)(6)(3)(54)22(1)(1)
Pre-tax income190222241292401749680698586601
Income tax expense(54)(81)(41)(59)(72)(107)(115)(122)(107)(122)
Net income144151207242346662586593493494
EPS — basic$1.96$2.04$2.80$3.27$4.68$8.89$7.87$7.98$6.75$6.83
EPS — diluted$1.91$1.99$2.74$3.21$4.57$8.67$7.73$7.88$6.69$6.79
Shares outstanding — basic (M)73747474747474747372
Shares outstanding — diluted (M)75767575767676757473

Showing the latest 10 of 18 fiscal years.

Source: SEC EDGAR XBRL company facts — figures as reported in each period's original filing (structured data begins ~2008). EPS and other per-share figures are as reported and are not adjusted for later stock splits; a ⚑ marks a period where the reported share count changed by a large factor. Dollar figures in millions unless per-share. Line items a company never reports are omitted. Where a filer switched XBRL concepts, the successor concept is used and definitions can differ slightly (e.g. cash may include restricted cash; banks' revenue is net of interest expense; cost of revenue may exclude D&A; net income may be the amount available to common stockholders; debt issued/repaid may be net of issuance costs or include finance-lease obligations — each only where the original concept stopped being reported). Click a period header to open that period's source filing on EDGAR.